Teoman Deger
Overview
Explore the profile of Teoman Deger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
60
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isebia K, de Jong A, van Dessel L, de Weerd V, Beaufort C, Helmijr J, et al.
Mol Oncol
. 2025 Mar;
PMID: 40084488
Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration-resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test-sequencing...
2.
Fu S, Deger T, Boers R, Boers J, Doukas M, Gribnau J, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835478
Aberrant DNA methylation changes have been reported to be associated with carcinogenesis in cirrhotic HCC, but DNA methylation patterns for these non-cirrhotic HCC cases were not examined. Therefore, we sought...
3.
Eikenboom E, Wilting S, Deger T, Srebniak M, van Veghel-Plandsoen M, Boers R, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760576
Colorectal cancer (CRC) colonoscopic surveillance is effective but burdensome. Circulating tumor DNA (ctDNA) analysis has emerged as a promising, minimally invasive tool for disease detection and management. Here, we assessed...
4.
Isebia K, Mostert B, Deger T, Kraan J, de Weerd V, Oomen-de Hoop E, et al.
Mol Oncol
. 2023 May;
17(9):1898-1907.
PMID: 37178439
Multiple prognostic biomarkers, including circulating tumour cell (CTC) counts, exist in metastatic castration-resistant prostate cancer (mCRPC) patients, but none of them have been implemented into daily clinical care. The modified...
5.
Bos M, Deger T, Sleijfer S, Martens J, Wilting S
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628441
methylation was proposed as mechanism for endocrine resistance in metastatic breast cancer patients. To evaluate its potential as a minimally invasive biomarker, we investigated the feasibility of measuring methylation in...
6.
Verschoor N, Deger T, Jager A, Sleijfer S, Wilting S, Martens J
Cancer Treat Rev
. 2022 Apr;
106:102384.
PMID: 35366566
Addition of HER2-targeted treatment in breast cancer is mainly determined by the HER2-receptor status of primary breast cancer tissue, since longitudinal sampling is burdensome and often not feasible. However, tumor...
7.
Mendelaar P, Robbrecht D, Rijnders M, de Wit R, de Weerd V, Deger T, et al.
Mol Oncol
. 2022 Feb;
16(10):2086-2097.
PMID: 35181986
Second-line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour-derived DNA (ctDNA) levels may guide patient stratification, provided...
8.
Deger T, Mendelaar P, Kraan J, Prager-van der Smissen W, van der Vlugt-Daane M, Bindels E, et al.
Mol Oncol
. 2021 Dec;
16(16):2981-3000.
PMID: 34964258
Intrapatient tumour heterogeneity is likely a major determinant of clinical outcome in cancer patients. To assess heterogeneity in a minimally invasive manner, methods to perform single circulating tumour cell (CTC)...
9.
Deger T, Boers R, de Weerd V, Angus L, van der Put M, Boers J, et al.
Clin Epigenetics
. 2021 Oct;
13(1):196.
PMID: 34670587
Background: DNA methylation detection in liquid biopsies provides a highly promising and much needed means for real-time monitoring of disease load in advanced cancer patient care. Compared to the often-used...
10.
Jongbloed E, Deger T, Sleijfer S, Martens J, Jager A, Wilting S
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33920135
Monitoring treatment response in metastatic breast cancer currently consists mainly of radiological and clinical assessments. These methods have high inter-observer variation, suboptimal sensitivity to determine response to treatment and give...